Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Carbetocin (LV-101) for Prader-Willi Syndrome
NCT03649477Phase 3Completed
- Sponsor
- Levo Therapeutics
- Start
- Nov 2018
- Primary completion
- May 2020
- Modality
- Peptides
- Countries
- 3
01
Overview
A Phase 3 trial of carbetocin in Prader-Willi syndrome (PWS), sponsored by Levo Therapeutics. Started Nov 2018; status: completed.
02
Drugs
carbetocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03649477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649477.